Abstracts tagged "Lipids"

Abstract Number: 342 • 2013 ACR/ARHP Annual Meeting
TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
Julio C. B. Moraes¹, Carla G.S. Saad¹, Ana Cristina Ribeiro², Claudia G Schainberg³, Celio R. Gonçalves², Percival D Sampaio-Barros¹ and Eloisa Bonfá², ¹Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) patients have increased cardiovascular morbidity and mortality. Altered lipid profile is an important risk factor for the development of these complications.…
Abstract Number: 334 • 2013 ACR/ARHP Annual Meeting
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
Michael Lucke¹, Soo Hyun Kim² and M. Elaine Husni³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Cardiovascular disease risk is elevated in psoriatic arthritis (PsA) compared to the general population. Prior studies have demonstrated suboptimal evaluation and control of modifiable…
Abstract Number: 243 • 2013 ACR/ARHP Annual Meeting
The Association Between Metabolic Syndrome and Hand Osteoarthritis – Data From The Framingham Study
Ida K. Haugen¹, Vasan Ramachandran^2,3, Devyani Misra⁴, Tuhina Neogi⁴, Jingbo Niu⁴, Yuqing Zhang⁵ and David T. Felson⁵, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA, ³Cardiology, Boston University School of Medicine, Boston, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Metabolic factors may have a negative effect on cartilage, and may be especially relevant in the pathogenesis of hand OA. Our aim was to…
Abstract Number: 58 • 2013 ACR/ARHP Annual Meeting
Saturated Fatty Acids Act Synergistically With Interleukin 1 Beta To Increase Inflammation, Endoplasmic Reticulum Stress and Cell Death In Human Articular Chondrocytes
Oscar Alvarez-Garcia¹, Nicole H Rogers², Roy G Smith³ and Martin K. Lotz¹, ¹Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ²California Institute for Biomedical Research (Calibr), La Jolla, CA, ³Department of Metabolism and Aging, Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL
Background/Purpose: Obesity is a major risk factor for the development of osteoarthritis (OA). Altered biomechanics have been postulated as the main causative mechanism, but recent…
Abstract Number: 52 • 2013 ACR/ARHP Annual Meeting
Altered Lipid Metabolism In Osteoarthritis With Subsequent Proinflammatory Properties Of Apolipoprotein A-I
Dominique de Seny¹, Gaël Cobraiville², Edith Charlier³, Sophie Neuville², Laurence Lutteri⁴, Denis Malaise⁵, Olivier Malaise³, Jean-Paul Chapelle⁴, Biserka Relic¹ and Michel G. Malaise¹, ¹Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ²GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ³Department of Rheumatology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ⁴Medical Chemistry - CHU Liège, Liège, Belgium, ⁵University of Liège, Liège, Belgium
Background/Purpose: Osteoarthritis (OA) is associated with a local inflammatory process. It is now considered as a metabolic syndrome rather than due to aging or mechanical…
Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed⁴, Jeffrey D. Greenberg⁵, Ashwini Shewade², Daniel H. Solomon⁶, Joel M. Kremer⁷ and Tanya Sommers⁴, ¹Columbia University, New York, NY, ²Genentech Inc., South San Francisco, CA, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴CORRONA, Inc., Southborough, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 2309 • 2013 ACR/ARHP Annual Meeting
Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients
Katherine P. Liao¹, Jonathan Brown², Jonathan S. Coblyn³, Paul Cohen², Jorge Plutzky² and Daniel H. Solomon⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Cardiovascular (CV) risk is higher among rheumatic disease patients than the general population. However, CV risk management guidelines calibrated for the rheumatic disease population…
Abstract Number: 1249 • 2012 ACR/ARHP Annual Meeting
The Impact of Statin Use On Lipid Levels in Statin-Naive Patients with Rheumatoid Arthritis (RA) Vs. Non-RA Subjects: Results From a Population-Based Study
Elena Myasoedova¹, Cynthia S. Crowson², Abigail B. Green², Eric L. Matteson³ and Sherine E. Gabriel⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Dyslipidemia in patients with rheumatoid arthritis (RA) is well recognized. The impact of lipid-lowering medications on lipid levels in patients with RA vs non-RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].